查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993607

全球特發性肺纖維化市場：按治療方法和地區分類－市場規模、產業趨勢、機會分析和未來預測（2026-2035 年）

Global Idiopathic Pulmonary Fibrosis Market: By Therapy, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計未來十年，特發性肺纖維化 (IPF) 市場將顯著成長，反映出市場對有效治療方法的需求不斷成長以及醫療技術的進步。到 2025 年，市場規模預計將達到約 29.7069 億美元，到 2035 年，這一數字預計將加倍以上，達到 67.3649 億美元。這一顯著成長意味著 2026 年至 2035 年的複合年成長率 (CAGR) 將達到 9.4%，凸顯了市場成長的強勁勢頭。

目前，抗纖維化療法主導著特發性肺纖維化（IPF）市場，其中Pirfenidone和尼達尼布是用於延緩IPF進展的核心藥物。這些藥物已證實能有效抑制肺功能下降，進而改善患者的預後和生活品質（QOL）。它們在各個地區的廣泛應用凸顯了其在臨床實踐中的關鍵作用。然而，隨著研究日益聚焦於標靶治療和新型治療方法的開發，IPF市場正經歷轉型，這些療法和療法能夠更精準地針對疾病的潛在機制。

顯著的市場趨勢

特發性肺纖維化（IPF）市場集中度較高，少數幾家主要企業佔了大部分市場。這些主要企業憑藉著全面的產品系列、豐富的臨床經驗和完善的分銷網路，奠定了堅實的基礎。然而，隨著研發投入的增加和生技領域創新成果的湧現，這種集中格局正逐漸受到衝擊。

主要企業包括勃林格殷格翰、羅氏、Astra Zeneca和百時美施貴寶等老牌製藥巨頭。這些公司利用其雄厚的資源和豐富的經驗，推動治療藥物的研發，進行大規模臨床試驗，並獲得監管部門的核准。除了這些全球領導者外，像Priant Therapeutics、Fibrogen和Vicore Pharma這樣的小型生物技術公司也在不斷擴大其市場佔有率，它們專注於創新作用機制，並針對IPF進展過程中涉及的特定通路。

目前，特發性肺纖維化（IPF）市場主要由兩款產品支撐：基因泰克公司生產的Esbury（Pirfenidone）和勃林格殷格翰公司開發的Ofev（尼達尼布）。這兩種藥物都已被證實能有效延緩疾病進展並改善患者的生活品質，因此成為IPF的標準治療方案。它們在各個地區的廣泛應用凸顯了其重要的臨床價值和商業性成功。

主要成長要素

特發性肺纖維化 (IPF) 市場正經歷快速擴張，主要促進因素是人口結構變化，尤其是60歲及以上老年人口的成長。此年齡層尤其容易罹患IPF，約佔確診患者的三分之二。隨著美國、歐盟和亞太地區等主要地區人口老化，預計IPF的盛行率也將隨之上升。這一人口趨勢顯著提升了對有效治療方法的需求，預計未來幾年IPF市場將保持強勁成長，複合年成長率 (CAGR) 也將保持在較高水平。

新機會的趨勢

將人工智慧（AI）引入高解析度電腦斷層掃描（HRCT）影像的解讀，顯著提高了特發性肺纖維化（IPF）的診斷水平，有助於臨床實踐的標準化和準確性提升。傳統上，使用HRCT診斷IPF需要識別複雜的肺部影像模式，例如蜂窩狀改變，這些模式非常細微，放射科醫生難以準確識別。人為解讀的差異常導致診斷延遲或誤診，影響患者的預後和治療的及時性。然而，人工智慧演算法的引入正在迅速改變這一現狀，為放射科醫生提供了一個強大的工具，以增強其檢測能力並提高診斷信心。

最佳化障礙

高昂的治療費用是阻礙市場成長的一大挑戰。昂貴的治療方法往往會造成就醫障礙，尤其對於沒有全面醫療保險或居住在醫療預算有限地區的患者而言更是如此。當治療費用過高時，許多患者可能會推遲或放棄必要的治療。這不僅會影響個人的健康狀況，還會抑制整體市場需求。對於需要長期服藥的慢性病和複雜疾病，這種經濟負擔尤其沉重，因為隨著時間的推移，累積費用會顯著增加。

依細分市場分類

透過治療方法

  • 埃斯伯里（Pirfenidone）
  • Ofev（尼達尼布）
  • 蒂珀卡斯特
  • 帕姆列烏魯單抗
  • KD025
  • PRM 151
  • GKT831
  • 其他

國家

  • 美國
  • 英國
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 日本

依地區分類

  • 北美仍然是特發性肺纖維化 (IPF) 市場的絕對領導者，其中美國發揮主導作用。這種主導地位源自於多種因素，包括高診斷率（反映出完善的醫療基礎設施）和對疾病的廣泛認知。此外，該地區受益於成熟的保險報銷體系，使患者能夠便捷地獲得高品質的抗纖維化療法，這些療法對於控制和延緩 IPF 的進展至關重要。
  • 美國國立衛生研究院 (NIH) 於 2025 年進行的一項綜合Meta分析凸顯了特發性肺纖維化 (IPF) 在北美地區極高的盛行率，估計約為每 10 萬人中有 27.2 例。這一患病率顯著高於其他大洲，印證了該地區獨特的流行病學特徵。較高的診斷率（可能得益於更完善的篩檢和報告系統）導致患者數量不斷增加，從而為專注於 IPF 治療的製藥公司帶來了更大的商機。

主要市場參與企業

  • Genentech, Inc.
  • Boehringer Ingelheim Pharma GmbH, and Co. Kg
  • MediciNova
  • FibroGen, Inc.
  • Kadmon Corporation, LLC
  • Promedior
  • Genkyotex
  • CelgeneCorporation
  • ProMetic LifeSciences
  • Biogen, Inc.
  • Merck and Co.
  • Novartis
  • 其他主要企業

目錄

第1章：分析框架

  • 分析目的
  • 產品概述
  • 市場區隔

第2章 分析方法

  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：依地區分類
  • 本報告的前提條件
  • 市場規模估算
  • 數據檢驗

第3章摘要整理：全球特發性肺纖維化（IPF）市場

第4章 全球特發性肺纖維化（IPF）市場概述

  • 特發性肺纖維化概述
  • 產業價值鏈分析
    • 配方
    • 加工/包裝
    • 銷售代理
    • 最終用戶
  • 產業展望
    • 流行病學和患者人群
    • 目前治療方法
    • 未滿足的需求
    • 為IPF做出貢獻的組織
    • 關鍵意見領袖的觀點：特發性肺纖維化
    • 病例報告
    • 非處方藥
    • 正在研發中的藥物

（**未完待續，請見最終報告**）

  • PESTLE分析
  • 波特五力分析
    • 供應商議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 任務
    • 主要趨勢
  • 評估 COVID-19（冠狀病毒）對市場成長趨勢的影響
  • 市場成長及前景
    • 市場收益估算與預測（2017-2035）
    • 價格趨勢分析
  • 競爭格局概述
    • 市場集中度
    • 企業市場占有率分析（以金額為準，2020 年）
    • 競技地圖

第5章：特發性肺纖維化市場分析：依治療方法

  • 關鍵見解
  • 市場規模及預測（2017-2030 年）
    • 埃斯伯里（Pirfenidone）
    • Ofev（尼達尼布）
    • 蒂珀卡斯特
    • 帕姆列烏魯單抗
    • KD025
    • PRM 151
    • GKT831
    • 其他

第6章：特發性肺纖維化市場分析：依地區和國家分類

  • 關鍵見解
  • 市場規模及預測（2017-2030 年）
    • 美國
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 日本

第7章：美國特發性肺纖維化市場分析

第8章：英國特發性肺纖維化市場分析

第9章：法國特發性肺纖維化市場分析

第10章：德國特發性肺纖維化市場分析

第11章：義大利特發性肺纖維化市場分析

第12章：西班牙特發性肺纖維化市場分析

第13章：日本特發性肺纖維化市場分析

第14章：公司簡介

  • Genentech, Inc.
  • Boehringer Ingelheim Pharma GmbH and Co. Kg
  • MediciNova
  • FibroGen, Inc.
  • Kadmon Corporation, LLC
  • Promedior
  • Genkyotex
  • CelgeneCorporation
  • ProMetic LifeSciences
  • BioGen, Inc.
  • Merck and Co.
  • Novartis
  • 其他主要企業
簡介目錄
Product Code: AA0721084

The Idiopathic Pulmonary Fibrosis (IPF) market is poised for significant growth over the next decade, reflecting a rising demand for effective treatments and advancements in medical technology. In 2025, the market is projected to generate approximately US$ 2,970.69 million, with estimates indicating that this figure will more than double to reach US$ 6,736.49 million by 2035. This substantial expansion corresponds to a compound annual growth rate (CAGR) of 9.4% during the period from 2026 to 2035, highlighting the strong momentum behind market growth.

The market is currently dominated by antifibrotic therapies, with Pirfenidone and Nintedanib being the cornerstone medications prescribed to slow the progression of IPF. These drugs have demonstrated clinical efficacy in reducing lung function decline, thereby improving patient outcomes and quality of life. Their widespread adoption across various regions underscores their vital role in the treatment landscape. However, the IPF market is undergoing a shift as research increasingly focuses on the development of targeted and novel therapies aimed at addressing the underlying mechanisms of the disease more precisely.

Noteworthy Market Developments

The idiopathic pulmonary fibrosis (IPF) market is characterized by a moderate to high level of concentration, with a relatively small number of key players controlling a significant share of the market. These leading companies have established strong footholds through robust product portfolios, extensive clinical expertise, and well-developed distribution networks. However, this concentration is gradually being challenged by increasing research and development efforts and a surge of innovation emerging from the biotechnology sector.

Among the major companies dominating the IPF market are well-established pharmaceutical giants such as Boehringer Ingelheim, Roche, AstraZeneca, and Bristol Myers Squibb. These firms have leveraged their extensive resources and experience to advance therapeutic development, conduct large-scale clinical trials, and secure regulatory approvals. In addition to these global leaders, smaller biotech companies like Pliant Therapeutics, FibroGen, and Vicore Pharma are gaining traction by focusing on innovative mechanisms of action and targeting specific pathways involved in the progression of IPF.

Currently, the market's therapeutic landscape is anchored by two primary products: Esbriet (Pirfenidone), marketed by Genentech, Inc., and Ofev (Nintedanib), developed by Boehringer Ingelheim Pharma GmbH & Co. KG. Both drugs have become standard-of-care treatments for IPF due to their proven efficacy in slowing disease progression and improving patients' quality of life. Their widespread adoption across various regions underscores their clinical importance and commercial success.

Core Growth Drivers

The Idiopathic Pulmonary Fibrosis (IPF) market is experiencing rapid expansion, largely driven by demographic shifts, particularly the increasing size of the geriatric population aged 60 and above. This age group is especially vulnerable to IPF, with approximately two-thirds of diagnosed patients falling into this category. As populations in key regions such as the United States, the European Union, and the Asia-Pacific continue to age, the prevalence of IPF is expected to rise correspondingly. This demographic trend significantly fuels demand for effective therapies, positioning the IPF market for robust growth characterized by a high compound annual growth rate (CAGR) over the coming years.

Emerging Opportunity Trends

The integration of Artificial Intelligence (AI) into the interpretation of High-Resolution Computed Tomography (HRCT) scans has brought about a significant advancement in the diagnosis of idiopathic pulmonary fibrosis (IPF), contributing to greater standardization and accuracy in clinical practice. Traditionally, diagnosing IPF through HRCT involves identifying complex lung patterns, such as honeycombing, which can be subtle and challenging for radiologists to detect consistently. Variability in human interpretation has often led to delays or misdiagnoses, affecting patient outcomes and treatment timeliness. However, the incorporation of AI algorithms into the diagnostic process is rapidly transforming this landscape by providing radiologists with powerful tools to enhance detection and improve diagnostic confidence.

Barriers to Optimization

The high cost of treatment poses a significant challenge that could potentially hamper the growth of the market. Expensive therapies often create barriers to access, especially for patients who lack comprehensive insurance coverage or live in regions with limited healthcare funding. When treatment costs are prohibitive, many patients may delay or forgo necessary care, which not only affects individual health outcomes but also constrains the overall market demand. This financial burden can be particularly acute for chronic or complex conditions requiring long-term medication, where cumulative expenses add up substantially over time.

Segment Breakdown

By Therapy

  • Esbriet (Pirfenidone)
  • Ofev (Nintedanib)
  • Tipelukast
  • Pamrevlumab
  • KD025
  • PRM 151
  • GKT831
  • Others

By Country

  • The U.S.
  • The UK
  • France
  • Germany
  • Spain
  • Italy
  • Japan

Geography Breakdown

  • North America continues to hold its position as the undisputed leader in the idiopathic pulmonary fibrosis (IPF) market, with the United States serving as the primary driving force behind this dominance. This leadership stems from multiple factors, notably a high diagnosis rate that reflects advanced healthcare infrastructure and widespread awareness of the disease. Additionally, the region benefits from a well-established reimbursement environment, which facilitates patient access to premium antifibrotic therapies that are essential for managing and slowing the progression of IPF.
  • A comprehensive meta-analysis conducted by the National Institutes of Health (NIH) in 2025 highlights the significant regional prevalence of IPF in North America, estimating approximately 27.2 cases per 100,000 individuals. This prevalence rate markedly exceeds that found in other continents, underscoring the unique epidemiological characteristics of the region. The higher diagnosis rates, likely due to superior screening and reporting mechanisms, contribute to a larger patient pool and, consequently, a greater commercial opportunity for pharmaceutical companies specializing in IPF therapies.

Leading Market Participants

  • Genentech, Inc.
  • Boehringer Ingelheim Pharma GmbH, and Co. Kg
  • MediciNova
  • FibroGen, Inc.
  • Kadmon Corporation, LLC
  • Promedior
  • Genkyotex
  • CelgeneCorporation
  • ProMetic LifeSciences
  • Biogen, Inc.
  • Merck and Co.
  • Novartis
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Idiopathic Pulmonary Fibrosis (IPF) Market

Chapter 4. Global Idiopathic Pulmonary Fibrosis Market Overview

  • 4.1. Idiopathic Pulmonary Fibrosis Overview
  • 4.2. Industry Value Chain Analysis
    • 4.2.1. Formulation
    • 4.2.2. Processing & Packaging
    • 4.2.3. Distributor
    • 4.2.4. End users
  • 4.3. Industry Outlook
    • 4.3.1. Epidemiology and Patient Population
      • 4.3.1.1. Key Findings
      • 4.3.1.2. 7MM Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 4.3.1.3. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis
        • 4.3.1.3.1. United States
          • 4.3.1.3.1.1. Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States
          • 4.3.1.3.1.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.1.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.1.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.2. EU5
          • 4.3.1.3.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5
          • 4.3.1.3.2.2. UK
            • 4.3.1.3.2.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.2.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.2.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.2.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.3. France
            • 4.3.1.3.2.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.4. Germany
            • 4.3.1.3.2.4.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.4.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.4.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.4.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.5. Spain
            • 4.3.1.3.2.5.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.5.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.5.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.5.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.6. Italy
            • 4.3.1.3.2.6.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.6.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.6.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.6.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.3. Japan
          • 4.3.1.3.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
          • 4.3.1.3.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 4.3.2. Current Treatment Practices
      • 4.3.2.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
      • 4.3.2.2. Patient Journey
    • 4.3.3. Unmet Needs
    • 4.3.4. Organizations contributing toward IPF
    • 4.3.5. KOL's Views: Idiopathic Pulmonary Fibrosis
    • 4.3.6. Case Reports
      • 4.3.6.1. Idiopathic Pulmonary Fibrosis: As case Discussion in the US
      • 4.3.6.2. Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A Case Report of Europe
      • 4.3.6.3. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis - A Japanese Case Report
    • 4.3.7. Marketed Drugs
      • 4.3.7.1. Esbriet (Pirfenidone): Inter Mune Inc.
        • 4.3.7.1.1. Product Description
        • 4.3.7.1.2. Regulatory Milestones
        • 4.3.7.1.3. Clinical Development
        • 4.3.7.1.4. Ongoing Current Pipeline Activity
        • 4.3.7.1.5. Safety and efficacy
        • 4.3.7.1.6. Product Profile
      • 4.3.7.2. OFEV (Nintedanib): BoehringerIngelheim Pharma GmbH and Co. KG
        • 4.3.7.2.1. Regulatory Milestones
        • 4.3.7.2.2. Clinical Development
        • 4.3.7.2.3. Ongoing Current Pipeline Activity
        • 4.3.7.2.4. Safety and efficacy
        • 4.3.7.2.5. Product Profile
    • 4.3.8. Emerging Drugs
      • 4.3.8.1. Tipelukast: MediciNova
        • 4.3.8.1.1. Product Description
        • 4.3.8.1.2. Other Development Activities
        • 4.3.8.1.3. Clinical Development
        • 4.3.8.1.4. Clinical Trials Information
        • 4.3.8.1.5. Safety and Efficacy
        • 4.3.8.1.6. Product Profile
      • 4.3.8.2. Pamrevlumab: FibroGen
        • 4.3.8.2.1. Product Description
        • 4.3.8.2.2. Other Development Activities
        • 4.3.8.2.3. Clinical Development
        • 4.3.8.2.4. Clinical Trials Information
        • 4.3.8.2.5. Safety and Efficacy
        • 4.3.8.2.6. Product Profile
      • 4.3.8.3. KD025: Kadmon Corporation, LLCs
        • 4.3.8.3.1. Product Description
        • 4.3.8.3.2. Other Development Activities
        • 4.3.8.3.3. Clinical Development
        • 4.3.8.3.4. Clinical Trials Information
        • 4.3.8.3.5. Safety and Efficacy
        • 4.3.8.3.6. Product Profile

(**to be continued in final report)

  • 4.4. PESTLE Analysis
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Market Dynamics and Trends
    • 4.6.1. Growth Drivers
    • 4.6.2. Restraints
    • 4.6.3. Challenges
    • 4.6.4. Key Trends
  • 4.7. Covid-19 Impact Assessment on Market Growth Trend
  • 4.8. Market Growth and Outlook
    • 4.8.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 - 2030
    • 4.8.2. Price Trend Analysis
  • 4.9. Competition Dashboard
    • 4.9.1. Market Concentration Rate
    • 4.9.2. Company Market Share Analysis (Value %), 2020
    • 4.9.3. Competitor Mapping

Chapter 5. Idiopathic Pulmonary Fibrosis Market Analysis, By Therapy

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 5.2.1. Esbriet (Pirfenidone)
    • 5.2.2. Ofev (Nintedanib)
    • 5.2.3. Tipelukast
    • 5.2.4. Pamrevlumab
    • 5.2.5. KD025
    • 5.2.6. PRM 151
    • 5.2.7. GKT831
    • 5.2.8. Others

Chapter 6. Idiopathic Pulmonary Fibrosis Market Analysis, By Region/Country

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 6.2.1. The U.S.
    • 6.2.2. The UK
    • 6.2.3. France
    • 6.2.4. Germany
    • 6.2.5. Spain
    • 6.2.6. Italy
    • 6.2.7. Japan

Chapter 7. The U.S. Idiopathic Pulmonary Fibrosis Market Analysis

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 7.2.1. By Therapy

Chapter 8. The UK Idiopathic Pulmonary Fibrosis Market Analysis

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 8.2.1. By Therapy

Chapter 9. France Idiopathic Pulmonary Fibrosis Market Analysis

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 9.2.1. By Therapy

Chapter 10. Germany Idiopathic Pulmonary Fibrosis Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 10.2.1. By Therapy

Chapter 11. Italy Idiopathic Pulmonary Fibrosis Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 11.2.1. By Therapy

Chapter 12. Spain Idiopathic Pulmonary Fibrosis Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 12.2.1. By Therapy

Chapter 13. Japan Idiopathic Pulmonary Fibrosis Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 13.2.1. By Therapy

Chapter 14. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 14.1. Genentech, Inc.
  • 14.2. Boehringer Ingelheim Pharma GmbH and Co. Kg
  • 14.3. MediciNova
  • 14.4. FibroGen, Inc.
  • 14.5. Kadmon Corporation, LLC
  • 14.6. Promedior
  • 14.7. Genkyotex
  • 14.8. CelgeneCorporation
  • 14.9. ProMetic LifeSciences
  • 14.10. BioGen, Inc.
  • 14.11. Merck and Co.
  • 14.12. Novartis
  • 14.13. Other prominent players